Taking people in United StatesPhase 4
Studies how dupilumab affects immune cells in skin of people with atopic dermatitis
Tests dupilumab's effect on immune cells in skin lesions of adults with atopic dermatitis.
Plain-language title generated from the registry record
Registry title: Molecular Signatures of Cutaneous Dupilumab Response
Key facts
- Where
- San Francisco, United StatesSee the site
- Phase
- Phase 4
Where in United States
- University of California San FranciscoSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT05858619
- Record updated
- 4 June 2026
- Original description
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.Read full original descriptionShow less
Molecular Signatures of Cutaneous Dupilumab Response
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Inclusion: 18 years of age or older; atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7.
Exclusion: Known parasitic infection -; Known pregnancy; Known immunodeficiencies.